RT Journal Article
SR Electronic
T1 Prostad: The development and evaluation of a prostate cancer rapid diagnostic pathway, a protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.30.24308198
DO 10.1101/2024.05.30.24308198
A1 Jones, Katie
A1 Rees, Sarah
A1 Farrington, Steven
A1 Chandran, Arya
A1 Moosa, Sohail
A1 MacKrell, Janet
A1 Shanbhag, Savita
A1 Ng, Yeung
A1 Sewell, Berni
A1 Jones, Mari
A1 Erdem, Esra
A1 Fitzsimmons, Deborah
A1 Rich, Nick
A1 Rance, Jaynie
A1 Gemine, Rachel
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2024.05.30.24308198.abstract
AB Background Delay to cancer diagnosis is associated with poorer outcomes. In response to delays to cancer diagnosis in the UK, a number of Rapid Diagnosis Centres (RDCs), Multi-Disciplinary Centres (MDCs) and other pathway reforms have been piloted and implemented in recent years. Prostate cancer is the most commonly diagnosed cancer for men or those assigned male at birth in the UK. In Wales, the recommended time to diagnosis is within 62 days from point of suspicion. For patients served by Hywel Dda University Health Board, current waiting times on the prostate cancer diagnostic pathway are prolonged, falling well outside the 28-day decision to treat and 62-day referral to treatment targets. A revised prostate cancer diagnostic pathway called Prostad (Wesh for “prostate”) has been developed and is currently being implemented with the aim of reducing time to diagnosis (or discharge) for patients referred for investigation. This protocol describes Prostad and the planned evaluation approach.Methods This is a mixed-method evaluation. It is shaped by patient and public involvement throughout and incorporates realist interviews with multiple stakeholders (including NHS staff and patients), process mapping, economic evaluation, and monitoring of the intervention against its aims using routinely collected data.Discussion To the authors’ knowledge, this is the first project of its kind to combine service aims evaluation, cost-effectiveness analysis and realist evaluation approaches, and as such promises findings applicable to organisations and individuals with regard to various aims and priorities. Continued patient and public involvement throughout the study constitutes one of its strengths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The evaluation has been approved by the Research, Innovation and Value Based Health Care Department at Hywel Dda University Health Board NHS research ethics approval was not required for this health board-led evaluation. Swansea University Ethics Committee granted its favourable opinion on 9th January 2024.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.